CD19 and acute lymphoblastic leukemia: Human CAR T-cells engineered with purified CD19 IVT-mRNA exhibited a two-fold increase in cytotoxicity against the Nalm-6 cell line and a remarkable 100-fold reduction in leukemia burden in humanized ALL mice, demonstrating enhanced persistence.